Eplerenone treatment in recurred central serous chorioretinopathy

Purpose : To evaluate short-Term effects of eplerenone treatment for patients with recurred or prolonged central serous chorioretinopathy(CSC). Methods: This retrospective case series included 7 eyes of 6 CSC patients with persistent subretinal fluid(SRF) for more than 3 months. The patients orally took eplerenone 50mg/day for 3 to 6 months. The change of best-corrected visual acuity and resolution of subretinal fluid were examined. Results : The average duration of oral eplerenone treatment was 5.1 ±1.5 months. Complete resolution of SRF was achieved in 2 of the 7 eyes(2 of the 6 patients) at 3 months. Two of the 4 patients (2 of the 5 eyes) stopped the eplerenone treatment, because of incomplete resolution of SRF. At 6 months, only 2 of the 5 eyes(2 of the 4 patients) showed complete resolution of SRF. BCVA was not significantly improved. No significant side effects was observed during the treatment. Conclusions : Oral eplerenone treatment was not fully effective to resolve recurred or prolonged SRF in the CSC patients. BCVA was not significantly improved.